IP Library Granted Patent US 7,094,750
Granted Patent B2
US 7,094,750 · App. 09/851,422 · Granted Aug 22, 2006

Therapeutic pore-forming peptides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,094,750
App. No.
09/851,422
Granted
Aug 22, 2006
Kind
B2
Abstract

A class of procytotoxic agents is characterized by a capability to kill with target cell-specificity. Such an aspect can be a pore-forming protein which has at least one lysine residue, modified by a peptide linkage to an amino acid residue, via the epsilon amino group. These agents are useful in treating cancer, especially prostate cancer.

Claims (33)

1. A procytotoxin comprising a peptide comprising at least one lysine residue bound via a peptide bond to at least one amino acid via the ε-amino group of said lysine residue, wherein said peptide without said modification is a cytotoxic peptide, and wherein said at least one amino acid bound via the ε-amino group of said lysine residue acts to prevent the peptide from forming a lytically active conformation, and wherein the cytotoxic peptide is a pore-forming cytolytic peptide.

2. The procytotoxin of claim 1 , wherein the pore-forming cytolytic peptide is selected from the group consisting of Ae I, cytolysin of sea anemone, aerolysin, amatoxin, amoebapore, amoebapore homolog from Entamoeba dispar , brevinin-1E, brevinin-2E, barbatolysin, cytolysin of Enterococcus faecalis , delta hemolysin, diphtheria toxin, E1 Tor cytolysin of Vibrio cholerae , equinatoxin, enterotoxin of Aeromonas hydrophila , esculentin, granulysin, haemolysin of Vibrio parahaemolyuicus , intermedilysin of Streptococcus intermedius , the lentivirus lytic peptide, leukotoxin of Actinobacillus actinomycetemcomitans , magainin, melittin, membrane-associated lymphotoxin, Met-enkephalin, neokyotorphin, neokyotorphin fragment 1, neokyotorphin fragment 2, neokyotorphin fragment 3, neokyotorphin fragment 4, NK-lysin, paradaxin, perform, perfringolysin O, theta-toxin of Clostridium perfringens , phallolysin, phallotoxin, and streptolysin.

3. The procytotoxin of claim 2 , wherein the cytolytic peptide is an amoebapore.

4. The procytotoxin of claim 3 , comprising the following structure: Gly-Phe-Ile-Ala-Thr-Leu-Cys-Thr-Lys(R)-Val-Leu-Asp-Phe-Gly-Ile-Asp-Lys(R)-Leu-Ile-Gln-Leu-Ile-Glu-Asp-Lys(R) (SEQ ID NO: 1), wherein at least one (R) is independently selected from the group consisting of [ε-γ]-Glu, [ε-γ]-Glu-[α-γ]-(Glu) 3-1 , [ε-α]-(Phe) 3-1 , [ε-α](Tyr) 1-3 , [ε-α]-(Trp) 1-3 , [ε-α]-(Lys) 1-3 and [ε-α]-(Arg) 1-3 , wherein [ε-γ] represents a peptide bond between the epsilon amino group of lysine and the gamma carboxyl group of the adjacent glutamate, [α-γ] represents a peptide bond between the alpha amino group of the first glutamate and the gamma carboxyl group of the second glutamate, [ε-γ] represents a peptide bond between the epsilon amino acid of lysine and the alpha carboxyl group of the indicated amino acid and the subscript indicates that additional numbers of the designated amino acid can be linked to the first via conventional peptide bonds.

5. The procytotoxin of claim 2 , wherein the cytolytic peptide is a melittin.

6. The procytotoxin of claim 5 , consisting essentially of the following structure: Gly-Ile-Gly-Ala-Val-Leu-Lys(R)-Val-Leu-Thr-Thr-Gly-Leu-Pro-Ala-Leu-Ile-Ser-Trp-Ile-Lys(R)-Arg-Lys(R)-Arg-Gln-Gln (SEQ ID NO: 2), wherein at least one (R) is independently selected from the group consisting of [ε-γ]-Glu, [ε-γ]-Glu-[α-γ]-(Glu) 1-3 , [ε-α]-(Phe) 1-3 , [ε-α]-(Tyr) 1-3 , [ε-α]-(Trp) 1-3 , [ε-α]-(Lys) 1-3 and [ε-α]-(Arg) 1-3 , wherein [ε-γ] represents a peptide bond between the epsilon amino group of lysine and the gamma carboxyl group of the adjacent glutamate, [ε-γ] represents a peptide bond between the alpha amino group of the first glutamate and the gamma carboxyl group of the second glutamate, [ε-α] represents a peptide bond between the epsilon amino group of lysine and the alpha carboxyl group of the indicated amino acid and the subscript indicates that additional numbers of the designated amino acid can be linked to the first via conventional peptide bonds.

7. A procytotoxin comprising a peptide comprising at least one lysine residue bound via a peptide bond to at least one amino acid via the ε-amino group of said lysine residue, wherein said peptide without said modification is a cytotoxic peptide, and wherein said at least one amino acid bound via the ε-amino group of said lysine residue acts to prevent the peptide from forming a lytically active conformation, and wherein said procytotoxin comprises a structure selected from the group consisting of: N-Gly-Phe-Ile-Ala-Thr-Leu-Cys-Thr-Lys-Val- Leu-Asp-Phe-Gly-Ile-Asp-Lys-Leu-Ile-Gln-Leu-Ile-Glu-Asp-Lys([ε-γ]-Glu-[α-γ]-Glu)-CONH 2 (SEQ ID NO: 8) and NH 2 -Gly-Ile-Gly-Ala-Val-Leu-Lys-Val-Leu-Thr-Thr-Gly-Leu-Pro-Ala-Leu-Ile-Ser-Trp-Ile-Lys-([ε-γ]-Glu-[α-γ]-Glu)-Arg-Lys([ε-γ]-Glu-[α-γ]-Glu)-Arg-Gln-Gln-COOH (SEQ ID NO: 12).

8. A pharmaceutical composition, comprising the procytotoxin of claim 1 , and a pharmaceutically acceptable excipient.

9. A method for selectively destroying a target cell that is a cancer cell, comprising contacting the target cell with a procytotoxin, which comprises a peptide comprising at least one lysine residue bound via a peptide bond to at least one amino acid via the ε-amino group of said lysine residue, wherein said peptide without said modification is a cytotoxic peptide, and wherein said at least one amino acid bound via the ε-amino group of said lysine residue acts to prevent the peptide from forming a lytically active conformation, and wherein the cytotoxic peptide is a pore-forming cytolytic peptide.

10. The method of claim 9 , wherein said cancer cell is selected from the group consisting of prostate, ovarian, lung and skin cells.

11. The method of claim 9 , wherein the pore-forming cytolytic peptide is selected from the group consisting of Ae I, cytolysin of sea anemone, aerolysin, amatoxin, amoebapore, amoebapore homolog from Entamoeba dispar , brevinin-1E, brevinin-2E, barbatolysin, cytolysin of Enterococcus faecalis , delta hemolysin, diphtheria toxin, El Tor cytolysin of Vibrio cholerae , equinatoxin, enterotoxin of Aeromonas hydrophila , esculentin, granulysin, haemolysin of Vibrio parahaemolyticus , intermedilysin of Streptococcus intermedius , the lentivirus lytic peptide, leukotoxin of Actinobacillus actinomycetemcomitans , magainin, melittin, membrane-associated lymphotoxin, Met-enkephalin, neokyotorphin, neokyotorphin fragment 1, neokyotorphin fragment 2, neokyotorphin fragment 3, neokyotorphin fragment 4, NK-lysin, paradaxin, perform, perfringolysin O, theta-toxin of Clostridium perfringens , phallolysin, phallotoxin, and streptolysin.

12. The method of claim 11 , wherein the cytolytic peptide is an amoebapore.

13. The method of claim 11 , wherein the procytotoxin comprises the following structure; Gly-Phe-Ile-Ala-Thr-Leu-Cys-Thr-Lys(R)-Val-Leu-Asp-Phe-Gly-Ile-Asp- Lys(R)-Leu-Ile-Gln-Leu-Ile-Glu-Asp-Lys(R) (SEQ ID NO: 1), wherein at least one (R) is independently selected from the group consisting of [ε-γ]-Glu, [ε-γ]-Glu-[α-γ]-(Glu) 1-3 , [ε-α]-(Phe) 1-3 , [ε-α]-(Tyr) 1-3 , [ε-α]-(Trp) 1-3 , [ε-α]-(Lys) 1-3 and [ε-α]-(Arg) 1-3 , wherein [ε-γ] represents a peptide bond between the epsilon amino group of lysine and the gamma carboxyl group of the adjacent glutamate, [α-γ] represents a peptide bond between the alpha amino group of the first glutamate and the gamma carboxyl group of the second glutamate, [ε-α] represents a peptide bond between the epsilon amino acid of lysine and the alpha carboxyl group of the indicated amino acid and the subscript indicates that additional numbers of the designated amino acid can be linked to the first via conventional peptide bonds.

14. The method of claim 11 , wherein the cytolytic peptide is a melittin.

15. The method of claim 14 , wherein the procytotoxin consists essentially of the following structure: Gly-Ile-Gly-Ala-Val-Leu-Lys(R)-Val-Leu-Thr-Thr-Gly-Leu-Pro-Ala-Leu-Ile-Ser-Trp-Ile- Lys(R)-Arg-Lys(R)-Arg-Gln-Gln (SEQ ID NO: 2), wherein at least one (R) is independently selected from the group consisting of [ε-γ]-Glu, [ε-γ]-Glu-[α-γ]-(Glu) 1-3 , [ε-α]-(Phe) 1-3 , [ε-α]-(Tyr) 1-3 , [ε-α]-(Trp) 1-3 , [ε-α]-(Lys) 1-3 and [ε-α]-(Arg) 1-3 , wherein [ε-γ] represents a peptide bond between the epsilon amino group of lysine and the gamma carboxyl group of the adjacent glutamate, [α-γ] represents a peptide bond between the alpha amino group of the first glutamate and the gamma carboxyl group of the second glutamate, [ε-α] represents a peptide bond between the epsilon amino group of lysine and the alpha carboxyl group of the indicated amino acid and the subscript indicates that additional numbers of the designated amino acid can be linked to the first via conventional peptide bonds.

16. A method for selectively destroying a target cell that is a cancer cell, comprising contacting the target cell with a procytotoxin, which comprises a peptide comprising at least one lysine residue bound via a peptide bond to at least one amino acid via the ε-amino group of said lysine residue, wherein said peptide without said modification is a cytotoxic peptide, and wherein said at least one amino acid bound via the ε-amino group of said lysine residue acts to prevent the peptide from forming a lytically active conformation, and the procytotoxin comprises the structure NH 2 -Gly-Ile-Gly-Ala-Val-Leu-Lys-Val-Leu-Thr-Thr-Gly-Leu-Pro-Ala-Leu-Ile-Ser-Trp-Ile-Lys ([ε-γ]-Glu- [α-γ]-Glu)-Arg-Lys([ε-γ]-Glu-[α-γ]-Glu)-Arg-Gln-Gln-COOH (SEQ ID NO: 12).

17. The procytotoxin of claim 1 , wherein the pore-forming cytolytic peptide is selected from the group consisting of Ae I, cytolysin of sea anemone, aerolysin, amatoxin, amoebapore, amoebapore homolog from Entamoeba dispar , brevinin-1E, brevinin-2E, barbatolysin, cytolysin of Enterococcus faecalis , delta hemolysin, diphtheria toxin, E1 Tor cytolysin of Vibrio cholerae , equinatoxin, enterotoxin of Aeromonas hydrophila , esculentin, granulysin, haemolysin of Vibrio parahaemolyticus , intermedilysin of Streptococcus intermedius , the lentivirus lytic peptide, leukotoxin of Actinobacillus actinomycetemcomitans , magainin, melittin, membrane-associated lymphotoxin, Met-enkephalin, neokyotorphin, neokyotorphin fragment 1, neokyotorphin fragment 2, neokyotorphin fragment 3, neokyotorphin fragment 4, NK-lysin, paradaxin, perform, perfringolysin O, theta-toxin of Clostridium perfringens , phallolysin, phallotoxin, and streptolysin.

18. The procytotoxin of claim 17 , wherein the cytolytic peptide is an amoebapore.

19. The procytotoxin of claim 18 , comprising the following structure: Gly-Phe-Ile-Ala-Thr-Leu-Cys-Thr-Lys(R)-Val-Leu-Asp-Phe-Gly-Ile-Asp-Lys(R)-Leu-Ile-Gln-Leu-Ile-Glu-Asp-Lys(R) (SEQ ID NO. 1), wherein at least one (R) is independently selected from the group consisting of [ε-γ]-Glu, [ε-γ]-Glu-[α-γ]-(Glu) 1-3 , [ε-α]-(Phe) 1-3 , [ε-γ]]-(Tyr) 1-3 , [ε-α]-(Trp) 1-3 , [ε-α]-(Lys) 1-3 and [ε-α]-(Arg) 1-3 , wherein:

[ε-γ] represents a peptide bond between the epsilon amino group of lysine and the gamma carboxyl group of the adjacent glutamate,

[α-γ] represents a peptide bond between the alpha amino group of the first glutamate and the gamma carboxyl group of the second glutamate,

[ε-α] represents a peptide bond between the epsilon amino acid of lysine and the alpha carboxyl group of the indicated amino acid, and

the subscript indicates that additional numbers of the designated amino acid can be linked to the first via conventional peptide bonds.

20. The procytotoxin of claim 19 , wherein R is independently selected from the group consisting of [ε-γ]-Glu and [ε-γ]-Glu-[α-γ]-(Glu) 1-3 , wherein:

[ε-γ] represents a peptide bond between the epsilon amino group of lysine and the gamma carboxyl group of the adjacent glutamate,

[α-γ] represents a peptide bond between the alpha amino group of the first glutamate and the gamma carboxyl group of the second glutamate, and

the subscript indicates that additional numbers of the designated amino acid can be linked to the first via conventional peptide bonds.

21. A method for selectively destroying a target cell that is a cancer cell, comprising contacting the target cell with a procytotoxin, which comprises a peptide comprising at least one lysine residue bound via a peptide bond to at least one amino acid via the ε-amino group of said lysine residue, wherein said peptide without said modification is a cytotoxic peptide, and wherein said at least one amino acid bound via the ε-amino group of said lysine residue acts to prevent the peptide from forming a lytically active conformation, and the procytotoxin comprises the structure N-Gly-Phe-Ile-Ala-Thr-Leu-Cys-Thr-Lys-Val-Leu-Asp-Phe-Gly-Ile-Asp-Lys-Leu-Ile-Gln-Leu-Ile-Glu-Asp-Lys([ε-γ]-Glu-[α-γ]-Glu)-CONH 2 (SEQ ID NO. 8).

22. A procytotoxin comprising a peptide comprising at least one lysine residue bound via a peptide bond to at least one amino acid via the ε-amino group of said lysine residue,

(i) wherein said peptide without the modification is a pore-forming cytolytic peptide,

(ii) wherein said at least one amino acid bound via the ε-amino group of said lysine residue acts to prevent the peptide from forming a lytically active conformation, and

(iii) wherein said cytolytic peptide need not be internalized to cause target-specific cell death.

23. The procytotoxin of claim 22 , wherein the pore-forming cytolytic peptide is selected from the group consisting of amoebapore and melittin.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 14, 2014
From: WAGNER, THOMAS E.
To: ORBIS HEALTH SOLUTIONS LLC
Reel/Frame 032665/0086 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 31, 2009
From: GHC RESEARCH DEVELOPMENT CORPORATION AND GREENVILLE HOSPITAL SYSTEM
To: WAGNER, THOMAS E.
Reel/Frame 023720/0296 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2009
From: ONCOLIX, INC.
To: GHC RESEARCH DEVELOPMENT CORPORATION
Reel/Frame 022980/0745 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2009
From: GHC RESEARCH DEVELOPMENT CORPORATION
To: ONCOLIX, INC.
Reel/Frame 022645/0833 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2007
From: GREENVILLE HOSPITAL SYSTEM
To: GHC RESEARCH DEVELOPMENT CORPORATION
Reel/Frame 019640/0640 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2005
From: YU, XIANZHONG; WAGNER, THOMAS E.
To: GREENVILLE HOSPITAL SYSTEM
Reel/Frame 016056/0727 →